15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata greatly affects people's life quality, mental health, and work life.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
4 citations
,
July 2024 in “The Journal of Dermatology” Alopecia areata in Dubai mostly affects men, often involves autoimmune disorders, and has high healthcare costs, especially for psychological issues.
4 citations
,
March 2022 in “Dermatology and Therapy” People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.
3 citations
,
March 2019 in “Case Reports” A man with myotonic dystrophy type 1 had 28 skin cancers, suggesting a link between the disease and skin cancer, emphasizing the need for sun protection and regular skin checks.
2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.